Advanced search
Publication Cover
Patient Preference and Adherence Volume 5, 2011 - Issue
Submit an article Journal homepage
93
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

Jian Chen1 Eli Lilly and Company
,
Haya Ascher-Svanum1 Eli Lilly and CompanyCorrespondence[email protected]
,
Allen W Nyhuis1 Eli Lilly and Company
,
Michael G Case1 Eli Lilly and Company
,
Glenn A Phillips1 Eli Lilly and Company
,
Kory J Schuh1 Eli Lilly and Company
&
Vicki Poole Hoffmann2 Lilly USA, LLC, Indianapolis, IN, USA
 show all
Pages 547-554 | Published online: 03 Nov 2011

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Kimberly M Shuler. (2014) Approaches to improve adherence to pharmacotherapy in patients with schizophrenia. Patient Preference and Adherence 8, pages 701-714.
Read now

Articles from other publishers (1)

Anne Emilie Stürup, Carsten Hjorthøj, Heidi Dorthe Jensen, Marianne Melau, Josefine Winther Davy, Merete Nordentoft & Nikolai Albert. (2023) Self‐reported reasons for discontinuation or continuation of antipsychotic medication in individuals with first‐episode schizophrenia. Early Intervention in Psychiatry.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.